This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Mogamulizumab for relapsed or refractory cutaneous T-cell lymphoma – second and subsequent lines. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma, a cancer affecting one type of white blood cell. At the beginning, lymphoma can be difficult to diagnose, but as the lymph nodes get bigger, a painless swelling in the neck, armpit or groin is sometimes noticed as well as raised, rash-like, itchy patches or lumps on the skin. By the time they are diagnosed, the lymphoma has often spread widely around the body. The main treatment is chemotherapy but as this disease mainly affects older people, not all patients are well enough to manage this, and the disease often returns after treatment.
Mogamulizumab is a new drug for the treatment of cutaneous T-cell lymphoma that is injected into the bloodstream weekly or fortnightly. It is being studied at the moment to see how well it works and whether it is safe to use. If it is licensed for use in the UK, it would be a new treatment option that could improve the life expectancy of patients whose lymphoma has returned after their first treatment has stopped working.
Subject indexing assigned by CRD
Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published